Healthy Subjects
Conditions
Brief summary
This study is being done to find out if IBI355 is safe and tolerance in health volunteers. The study will test increasing single doses of IBI355 given to adult health volunteers. The goal is to confirmed the safety of the highest dose of IBI355 or to find out the highest dose of IBI35 that can be given to health volunteer that dose not cause unacceptable side effects. Different dose regimens will be evaluated. The pharmacokinetics and ADA of IBI355 will also be evaluated.
Interventions
DRUGplacebo
placebo iv. once.
DRUGIBI355
IBI355 iv. once.
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Subjects who have decided to voluntarily participate in the study and provided a written consent regarding observance of precautions after having been informed of and having fully understood the objectives, methods, and effects of the study in detail; 2. Healthy male and female aged 18 years or above ; 3. Subject with a Body Mass Index (BMI)\* between 18.5 and 28.0 kg/㎡; 4. subjects with a normal laboratory examination，ECG， X-ray.
Exclusion criteria
1. Subjects with a history of allergy； 2. Subjects participated in the other clinical trail in 1 month or less than 5 t1/2 since the previous clinical trial (which is longer)； 3. Subjects with an infection requiring systemic medication was present within 30 days prior to randomization; 4. HIV-Ab、RPR、HCV-Ab、HBV、HBeAg or HBcAb, one of them positive; 5. There have a clinical or imaging evidence that the subject with active tuberculosis, or there is evidence that the subject is in the incubation period for tuberculosis; 6. Patients with a history of central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, metabolic disorders and other systemic diseases; 7. Subject with a hcg positive; 8. Patients with a history of neuropsychiatry or who are considered unfit to participate in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of AE、SAE after receiving IBI 355 | week 0-12 |
Secondary
| Measure | Time frame |
|---|---|
| Area Under Curve, (AUC）、Maximum serum concentration of drug(Cmax）、Clearance (CL）、Apparent volume of distribution(V） and Half- life(t1/2）of IBI355 | week 0-12 |
Countries
China
Outcome results
None listed